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Abstract
Background: Smoking while pregnant is associated with a myriad of negative health outcomes in the child. Some of the
detrimental effects may be due to epigenetic modifications, although few studies have investigated this hypothesis in
detail.
Objectives: To characterize site-specific epigenetic modifications conferred by prenatal smoking exposure within asthmatic
children.
Methods: Using Illumina HumanMethylation27 microarrays, we estimated the degree of methylation at 27,578 distinct DNA
sequences located primarily in gene promoters using whole blood DNA samples from the Childhood Asthma Management
Program (CAMP) subset of Asthma BRIDGE childhood asthmatics (n = 527) ages 5–12 with prenatal smoking exposure data
available. Using beta-regression, we screened loci for differential methylation related to prenatal smoke exposure, adjusting
for gender, age and clinical site, and accounting for multiple comparisons by FDR.
Results: Of 27,578 loci evaluated, 22,131 (80%) passed quality control assessment and were analyzed. Sixty-five children
(12%) had a history of prenatal smoke exposure. At an FDR of 0.05, we identified 19 CpG loci significantly associated with
prenatal smoke, of which two replicated in two independent populations. Exposure was associated with a 2% increase in
mean CpG methylation in FRMD4A (p = 0.01) and Cllorf52 (p = 0.001) compared to no exposure. Four additional genes,
XPNPEP1, PPEF2, SMPD3 and CRYGN, were nominally associated in at least one replication group.
Conclusions: These data suggest that prenatal exposure to tobacco smoke is associated with reproducible epigenetic
changes that persist well into childhood. However, the biological significance of these altered loci remains unknown.
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Introduction
Smoking while pregnant is associated with a myriad of negative
health outcomes both for the mother and for the fetus. [1] In utero
tobacco smoke exposure (IUS) can damage the placental structure
and function [2], is associated with changes in children’s
neurodevelopment and behavior [3] as well as with impaired lung
function and increased risk of developing asthma. [4,5,6]
Moreover, IUS-related deficits in lung function are larger for
children with asthma. [7].
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One hypothesized mechanism through which IUS may act is by
altering the epigenetic landscape within the developing fetus.
Increasingly, scientific reports are linking IUS exposure to
alterations in the fetal epigenome, including changes in DNA
methylation in numerous genes and tissue types. [8,9] To further
investigate the association between IUS and epigenetics, we
evaluated the association between IUS exposure and DNA
methylation in the first phase of subjects participating in the
Asthma BioRepository for Integrative Genomic Exploration
(Asthma BRIDGE) study - a subset of asthmatic children originally
from the Childhood Asthma Management Program (CAMP) trial.
[10,11] We designed a study aimed at investigating DNA
methylation in promoter regions of genes as these are the most
pertinent regulatory regions for gene expression. We interrogated
27,578 CpG loci using the Illumina HumanMethylation27
platform - a promoter-centric assay - measured in whole blood
samples collected in the CAMP population and replicated our
findings in two other populations: 1) the remainder of the Asthma
BRIDGE project with Illumina HumanMethylation450 (HM450)
data; and 2) the Norwegian Mother and Child Cohort Study
(MoBa).
Methods
Study Population
Asthma BRIDGE is a multicenter initiative to develop a
publicly accessible resource consisting of ,1,500 asthmatics and
controls with comprehensive phenotype and genomic data. The
first phase of the Asthma BRIDGE multicenter initiative consisted
of asthmatic subjects that were originally recruited as part of
CAMP, the details of which have been described elsewhere.
[10,11] Briefly, CAMP is a multicenter, randomized, double-
masked clinical trial to compare the long-term effectiveness and
safety of 3 inhaled treatments for asthma: budesonide, nedocromil,
and placebo. Asthma was defined by the presence of asthma
symptoms or the use of an inhaled bronchodilator at least twice
per week or use of a daily asthma medication for the 6 months
before the screening interview. All participants had increased
airway responsiveness to methacholine (PC20,12.5 mg/mL) at
study entry. Each parent or guardian signed a consent form and
each participant 7 years of age and older signed an assent form
approved by each clinical center’s institutional review board. Prior
to treatment randomization, DNA samples were collected from
968 of 1,041 willing CAMP participants, of which 572 were of self-
reported Western European ancestry. Of these, sufficient DNA for
methylation typing was available for 554 (97%). Mean age at DNA
collection was 9 years.
Replication was conducted in the remainder of Asthma
BRIDGE subjects and in MoBA.
Asthma BRIDGE had 526 participants for whom whole blood
samples with DNA methylation from the Illumina HM450 were
available, of whom 332 were asthmatic. Subjects were recruited
from five studies: Genomic Research on Asthma in the African
Diaspora (GRAAD), Children’s Health Study (CHS), Chicago
Asthma Genetics (CAG), Childhood Asthma Research and
Education (CARE), and Mexico City Childhood Asthma Study
(MCCAS). Descriptions of these cohorts are provided in File S1.
The primary objective of the Asthma BRIDGE initiative was to
create a biorepository of cell lines and accompanying datasets for
public access. All of the primary data analyzed for this study have
been submitted to BioLINCC (https://biolincc.nhlbi.nih.gov),
from where it will be made available to the public. The data is
also submitted to dbGaP (http://www.ncbi.nlm.nih.gov/gap)
within 6 months of publication.
The Norwegian Mother and Child Cohort Study (MoBa)
consisted of 1062 participants in whom the association between
maternal cotinine level and DNA methylation in cord blood was
recently assessed using Illumina’s Infinium HumanMethyla-
tion450 (HM450) BeadChip. [8] Maternal plasma cotinine
concentrations in the MoBa samples were measured using liquid
chromatography–tandem mass spectrometry. [12].
Ethics Statement
Written informed consent was provided by all study subjects.
The institutional review boards (IRB) of the Brigham and
Women’s Hospital, and each of the participating CAMP study
centers, approved these protocols. The MoBa study was approved
Norwegian Data Inspectorate and the Regional Ethics Committee
for Medical Research and the NIEHS Institutional Review Board.
Maternal Smoking Exposure
Information regarding IUS exposure was obtained during the
baseline medical interview for CAMP and Asthma BRIDGE
subjects. Children were considered to have IUS exposure if
respondents answered affirmatively to the question, ‘‘Did this
child’s mother smoke while she was pregnant with this child?’’
Information about current environmental tobacco smoke exposure
was obtained during follow-up interviews with the question, ‘‘Do
any caretakers of the child currently smoke cigarettes?’’ In MoBa,
cotinine concentrations were measured in maternal samples
collected at about 18 weeks of pregnancy using liquid chroma-
tography–tandem mass spectrometry. [12,13]
DNA Methylation
Laboratory personnel performing DNA methylation analysis
were blinded to study subject information. DNA was extracted
whole blood cells using the QiaAmp DNA blood kit (Qiagen Inc,
Valencia, CA) and stored at 280 degrees Celcius. Two
micrograms of genomic DNA from each sample were treated
with bisulfite using the EZ-96 DNA Methylation Kit (Zymo
Research, Irvine, CA, USA), according to the manufacturer’s
recommended protocol and eluted in 18 ul. The results of the
HM27 assay were compiled for each locus as previously described
and were reported as beta (b) values. [14] Details of quality control
procedures, dilution control series, and calculation of b values are
provided in File S1.
CpG loci on the HM27 array were removed from analyses if
they were on the X and Y chromosomes, or if they contained
SNPs, deletions, repeats, or if they mapped to multiple places in
the genome. A Normal exponential background correction was
first applied to the raw intensities at the array level to reduce
background noise. [15] We then normalized each sample’s
methylation values to have the same quantiles to address sample
to sample variability. [16] Lastly, we applied COMBAT, a mixed
effects model that accounted for exposure, to reduce probe level
variation. [17] The density plots after each step are shown in
Figure S1 (in File S1), and illustrate the improvement acquired
from each correction applied.
Samples from 554 CAMP participants were included for initial
analysis of DNA methylation. Six samples were excluded for
having methylation call rates ,95% and an additional 17 were
excluded because their sample mean methylation across all probes
was greater than 2 standard deviations from the overall mean of all
samples on the plate. Two additional samples were removed for
discrepancy of sex determination when comparing questionnaire
response data to X chromosome methylation patterns. One
additional sample was removed for missing IUS exposure and
Maternal Smoking and CpG Methylation
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another was removed before COMBAT correction for being the
only sample on a single chip. This left 527 samples for analysis.
mRNA Expression
Paired samples of isolated mRNA and DNA collected at the
same point in time were available for the Asthma BRIDGE
replication dataset only. We collected 5 cc of whole blood in RNA
PaxGene tubes. Samples were shipped to the data coordinating
center monthly for RNA extraction using the PAXgene Blood
RNA Kit according to manufacturer’s protocol (PreAnalytix).
Expression profiles were generated using the Illumina Human
HT-12 v4 arrays, according to manufacturers’ protocol (Illumina,
San Diego CA). Preprocessing was performed using quantile
normalization with the lumi Bioconductor package. [18] Evidence
for association between CpG methylation and target gene
expression was assessed using linear regression, including adjust-
ment for age, gender, and clinical center.
Statistical Analyses
Descriptive analyses were performed to examine the distribution
of subject characteristics. Density plots of DNA methylation values
were created and evaluated for quality control. Outlier DNA
methylation values were identified as values that were either
greater than the median+3*IQR or less than the median- 3*IQR
and were removed from analyses.
To investigate the association between IUS exposure and
percent DNA methylation, we fitted beta regression models
adjusted for age, sex, clinic and cell type. The following cell types
were estimated using the method of Houseman et al [19]: B-
lymphocytes, granulocytes, monocytes, natural killer cells, CD4+
T-lymphocytes, and CD8+ T-lymphocytes. Beta regression was
used to address the non-normal distribution of DNA methylation
values, which are bounded by 0 and 1 and in many cases heavily
skewed toward one end or the other. [20] The beta regression
model is as follows: Let y1,…,yn be a random sample of DNA
methylation beta values for a single feature on the HM27 assay.
We assume yi,Beta(mi,w), i = 1,…,n, with E(y) = m and
Var(y) = m(1-m)/(1+w), the parameter w measuring precision. The
regression model is defined as logit(mi) = a+a1 Xi1+…+ ak Xik, with
X1 measuring IUS exposure and X2,…,Xk measuring age, sex,
clinic, and estimated cell type fractions for B-lymphocytes,
granulocytes, monocytes, natural killer cells, CD4+ T-lympho-
cytes, and CD8+ T-lymphocytes. The precision parameter is
assumed constant for all observations. All regressions were run in
R using the betareg package (version R2.15.3).
Beta regression requires the data to be between zero and one,
therefore a shrinkage method was applied to force the zeros to be
positive as follows: 0.999999*(meth value-0.5) +0.5. Because beta
regression is modeled on the logit scale, we also present estimates
from linear regression models to provide interpretation of a %
difference in methylation and compare effect estimates to those
from our replication population. All regression analyses were
adjusted for multiple testing at a false discovery rate (FDR) of 0.05,
using the method of Benjamini and Hochberg. [21]
To investigation the association between methylation or IUS
and expression, linear regression models were fit in which
expression values were transformed on the log2 scale. Sensitivity
analyses were conducted in regression models of our top 19 loci to
evaluate potential confounding by the following covariates:
income, education, parental history of asthma, asthma severity,
maternal or paternal smoking in childhood. To replicate results,
we ran identical models in the 526 participants in Asthma
BRIDGE, as well as within asthmatics only. We also compared
our results to those from a study of 1062 participants from the
Norwegian Mother and Child Cohort Study. [8] Joubert et al
examined the association between maternal plasma cotinine
(active smoking defined as .56.8 nmol/L) and cytosine methyl-
ation in cord blood using robust linear regression on the log-ratio
of the methylation beta value obtained from the Illumina HM450
array, adjusting for several covariates.
All tests assumed a two-sided alternative hypothesis, a 0.05
significance level, and were conducted using the R programming
language, version R2.15.3.
Results
The HM27 assay demonstrated high reproducibility, with an
average spearman correlation coefficient of 0.96 across all
replicate control samples (i.e. PBL and dilution controls).
Additional analyses of accuracy, assessed by calculating bias
within the dilution controls, suggested minimal bias, with values of
0.15, 0.07, 20.03, and 20.11 for 10%, 35%, 60% and 85%
dilution controls, respectively.
Of the 527 children in the study, 65 (12.3%) were exposed to
maternal smoking during pregnancy. Age and sex did not vary
between exposed and unexposed children. However, unexposed
children were more likely to have a maternal (26%) or paternal
(21%) history of asthma compared to exposed children (16%).
Mothers who smoked during pregnancy also had significantly
lower education and income levels than mothers who did not
smoke (Table 1).
After application of background correction and normalization
procedures, we observed a total of 26 loci that were statistically
significantly associated with IUS at a FDR ,0.05. However, 7 of
these loci were removed from further consideration because their
mean methylation levels were less than 3% or greater than 97%
and thus largely invariant. The remaining 19 loci are shown in
Table 2.
We evaluated the 19 CpGs in two replication datasets (Tables
S1, S2 in File S1). In the Asthma BRIDGE replication population,
three of the 19 loci were not available. Of the remaining 16, four
loci had nominal p-values of less than 0.05: XPNPEP1 (p = 0.01),
PPEF2 (p = 0.003), FRMD4A (p = 0.01), C11orf52 (p = 0.04)
(Table 3, Figure 1). XPNPEP1 and PPEF2 remained statistically
significant after FDR adjustment for multiple testing. Moreover,
the results were consistent if we further restricted this population to
asthmatics only, to be more directly comparable to the CAMP
population, suggesting that the maternal smoking effects on these
genes are not restricted to asthmatic children. In MoBa, one locus
was not found in that dataset and four loci had nominal p-values of
less than 0.05: FRMD4A (p = 0.0009), C11orf52 (p = 0.001),
SMPD3 (p = 0.02), and CRYGN (p = 0.05) (Table 3). FRMD4A
and C11orf52 remained significant after further adjustment for
multiple testing. Interestingly, for some of these genes multiple
CpG loci within the gene exhibited similar effect sizes and were
located near the transcription start sites for FRMD4A, CRYGN,
and PPEF2 (Tables S3, S4 in File S1).
In the initial screening analysis, the model was adjusted only for
sex, age clinic, and cell type. We conducted additional analyses to
evaluate whether the association was confounded by other
potentially relevant factors. No evidence for confounding was
noted for income, education, parental history of asthma, asthma
severity, or exposure to paternal smoking in childhood (data not
shown). As expected, report of exposure to maternal smoking
during childhood was strongly associated with in utero smoke
exposure, reported in 57 (88%) of 65 in utero exposed children.
Evidence for collinear association by maternal smoking in
childhood was present for some but not all of the loci, in some
Maternal Smoking and CpG Methylation
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cases strengthening the association and in some cases decreasing
the association for prenatal tobacco smoke exposure (Table S5 in
File S1). For example, adjustment for childhood smoke exposure
had little to no effect on the estimate for prenatal smoke exposure
for C11orf52 and PPEF2. However, adjustment for childhood
smoke exposure attenuated the effect estimates for FRMD4A and
XPNPEP1.
The direction and magnitude of effect estimates for IUS
exposure was consistent in all datasets for all loci. Interestingly,
FRMD4A and C11orf52 showed consistently strong effect
estimates across all three diverse populations, regardless of
whether the children were asthmatic, and regardless of the timing
of sample collection. In fact, the use of cord blood in the MoBa
replication dataset lends support to the conclusion that the effects
on DNA methylation in FRMD4A and C11orf52 are due to
prenatal rather than childhood smoke exposure.
Lastly, in the Asthma BRIDGE replication population, we
evaluated the relation between DNA methylation and expression
for XPNPEP1, PPEF2, and FRMD4 as well as the association
between IUS and expression. C11orf52 could not be evaluated as
there was no associated mRNA transcript. Though expression
profiles in whole blood were available for 526 subjects, we did not
observe significant associations between methylation and expres-
sion for the three tested genes. However, expression of two of these
genes (PPEF2 and XPNPEP1) was significantly decreased in
subjects with IUS exposure compared to those without IUS
exposure (b=20.02, p = 0.02 for PPEF2; and b=20.05,
p = 0.01 for XPNPEP1), demonstrating that exposure was
associated both with changes in both methylation and expression
in the same sample.
Discussion
In a comprehensive investigation of IUS exposure and DNA
methylation in the offspring, we identified 19 CpG loci in whole
blood significantly associated with IUS in asthmatic children, two
of which (FRMD4A and C11orf52) were replicated in two
additional independent populations and four others that warrant
potential further investigation.
FRMD4A encodes a scaffolding protein involved in activation
of Arf6, which in turn, plays a role in membrane trafficking,
junctional remodeling and epithelial polarization. [22] Our
observation of increased DNA methylation in FRMD4A in whole
blood samples from children exposed to maternal smoking is
consistent with an experimental study showing hypermethylated
FRMD4A in MCF-7 cells treated with benzo(a)pyrene (BaP), a
common polycyclic aromatic hydrocarbon that is a constituent of
cigarette smoke. [23] Moreover, FRMD4A was recently identified
from a GWAS study in Asian populations and validated in
European and American populations as a gene associated with
nicotine dependence. [24] IUS exposure is also associated with
nicotine dependence in offspring. [25,26] These observations raise
the intriguing possibility that cigarette-smoke-induced epigenetic
modification of the FRMD4A gene plays a role in conferring
increased risk of nicotine dependence in offspring of mothers who
smoke during pregnancy. Beyond nicotine dependence, altered
DNA methylation of FRMD4A may have the potential to affect
other downstream health outcomes, since the gene has recently
been implicated as a risk factor for both Alzheimer’s disease and
squamous cell carcinoma. [27,28]
Very little is currently known about the other replicated locus
within C11orf52. C11orf52 describes an uncharacterized protein
that is expressed in the lung and which has been associated with
increased phosphorylation in non-small cell lung cancer tumor
Table 2. CpG Loci significantly associated with IUS exposure in CAMP asthmatics (N= 527).
Probe ID Symbol Chr Mean methylation level b* Difference in methylation** FDR p-value
cg05697249 C11orf52 11 0.66 0.09 0.02 0.001
cg14724265 PPEF2 4 0.76 0.17 0.03 0.01
cg25464840 FRMD4A 10 0.75 0.13 0.02 0.01
cg20588045 PCDH15 10 0.28 0.10 0.02 0.01
cg20555507 TRPM3 9 0.08 0.13 0.01 0.03
cg16184943 ZNF280B 22 0.34 20.09 20.02 0.03
cg09352789 XPNPEP1 10 0.29 20.06 20.01 0.03
cg07499072 FST 5 0.04 0.11 0.004 0.03
cg22830895 CRYGN 7 0.43 0.11 0.03 0.03
cg13473383 ZDHHC5 11 0.09 20.08 20.01 0.03
cg10556064 SMPD3 16 0.58 0.10 0.02 0.03
cg04112019 IGF2AS 11 0.12 0.07 0.01 0.03
cg00169548 BAZ1A 14 0.48 20.10 20.02 0.03
cg10493739 TMEM38B 9 0.06 20.07 20.004 0.03
cg01058368 CDH10 5 0.82 0.12 0.02 0.04
cg09143663 BACH1 21 0.72 0.08 0.02 0.04
cg20773127 ENPEP 4 0.58 0.10 0.02 0.05
cg24956866 CALD1 7 0.58 0.10 0.02 0.05
cg14580737 RFXANK 19 0.80 20.10 20.02 0.05
* coefficient from beta regression adjusted for age, sex, and clinic and cell type.
**coefficient from linear regression model illustrating difference in methylation level comparing IUS exposed to unexposed.
doi:10.1371/journal.pone.0099716.t002
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compared to normal tissue samples. [29] However, the C11orf52
locus also overlaps with heat shock 27kDa protein 2 (HSPB2).
HSPB2 is a stress-inducible small heat shock protein that plays a
role in airway smooth muscle (ASM) cell remodeling. HSPB2
undergoes rapid phosphorylation in the ASM cell thereby
stabilizing the cytoskeletal scaffolding and decreasing the rate of
microstructural reorganization. [30] ASM remodeling plays a role
in airway hyperresponsiveness and is a cardinal feature of asthma.
[31] Moreover, particulate matter exposure was shown to
stimulate reactive oxygen species generation in human lung
vascular endothelium, resulting in increased HSPB2 phosphory-
lation and a marked disruption in endothelial cell barrier function
via cytoskeletal rearrangement, key elements for lung homeostasis.
[32] Our observation of an IUS-induced change in CpG
methylation level in a locus within HSPB2 in asthmatic children
raises the interesting question of whether these changes directly
affect the function of or phosphorylation ofHSPB2 and could thus
play a role in airway remodeling.
XPNPEP1 and PPEF2 are two genes that may also be of
interest as they were significant in both the CAMP and Asthma
BRIDGE populations. However, little is known about these genes.
XPNPEP1 located on chromosome 10, encodes the human
soluble aminopeptidase P (APP) which is an aminoacylprolyl
hydrolase. [33] APP is a key enzyme in the renin-angiotensin and
kininogen-kinin hormonal systems and has been associated with
oral contraceptive use. [34] Specifically APP degrades bradykinin,
a blood pressure regulator peptide, and has been linked to
myocardial infarction. [35] PPEF2 is a protein phosphatase with
EF-hand domain whose function is not well understood. PPEF2
has also been implicated in dendritic cell development in a murine
model [36] and with schizophrenia in a small population. [37]
PPEF2 expression correlates with stress protective responses, cell
survival, growth and proliferation and is a negative regulator of
apoptosis signal regulating kinase-1 (ASK1), important in cancer,
cardiovascular, and neurodegenerative diseases. [38,39] Our
observation that IUS was associated with decreased expression
in PPEF2may not be surprising, given PPEF2’s purported role in
stress response. However, we provide some of the first evidence for
an association between IUS exposure and expression and CpG
methylation in both PPEF2 and XPNPEP; thus, a much greater
understanding of the biological roles of these genes is necessary
before we can understand the health implications of IUS on them.
SMPD3 and CRYGN are additional genes for which DNA
methylation was significantly associated with IUS exposure in both
the CAMP and MoBA, but did not meet the stringent criteria for
replication after adjustment for multiple testing. SMPD3 is the
Figure 1. Boxplots showing the distribution of % CpG methylation after normalization and batch correction using COMBAT by IUS
exposure for A) C11orf52 (cg05697249), B) XPNPEP1 (cg09352789), C) FRMD4A (cg25464840), and D) PPEF2 (cg14724265) in 526
Asthma BRIDGE samples.
doi:10.1371/journal.pone.0099716.g001
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primary regulator of ceramide biosynthesis, and plays a pivotal
role in the control of late embryonic and postnatal development
such that defects in the gene lead to dwarfism and pituitary
hormone deficiency. [40,41] SMPD3 has also been implicated in
macrophage differentiation and leukemia. [42] Given SMPD3’s
crucial role in development and its expression in neurons in the
central nervous system, our observed association with IUS raises
intriguing questions about the biological mechanisms underlying
smoking’s affect on prenatal growth. Lastly, CRYGN encodes a
crystallin, one of the main structural proteins in the eye. [43] Very
little research on CRYGN currently exists, thus the implications of
our association with IUS with regard to developmental biology are
largely unknown.
In this study, the associations between IUS and DNA
methylation of several genes were observed using questionnaire-
based recall of maternal smoking as well as measured cotinine
levels in cord blood. While questionnaire-based recall of maternal
smoking history is susceptible to recall bias, the positive findings
reported in a previous analysis in the CAMP cohort supports the
validity of the retrospective history. [44] DNA methylation was
measured both at birth in cord blood (MoBa) and in whole blood
at age 9 (CAMP) and in adults (Asthma BRIDGE). Our robust
results suggest the IUS effects on DNA methylation may persist
over years at least for some genes. An additional strength of our
use of cord blood for replication is that we remove potential
confounding effects of childhood maternal or paternal smoking
exposure, and can more confidently conclude the observed effects
are due to in utero exposure. On the other hand, because our
primary and replication studies were performed using whole blood
collected at different time points, we may have missed transient yet
important effects on DNA methylation.
DNA methylation was measured in whole blood, composed of a
variable mixture of circulating cell types. In theory, a shift in cell
populations caused by IUS, rather than differences in DNA
methylation, could explain our observed results. In order for this to
be true, however, IUS would have to alter the proportions of cell
populations not only at birth but 9 or more years later. To shed
further light on this possibility, we estimated 6 cell types using the
method of Houseman et al [19] and included these estimated cell
types as covariates in the regression model. Additionally, we tested
whether IUS exposure was associated with cell type and found no
association. Given these results, it is unlikely that differences in cell
types are accounting for our observed associations. Because we
evaluated DNA methylation in whole blood, we do not know
whether these same observations would be apparent in other tissue
or cell types of interest.
DNA methylation in our loci was not highly correlated with
expression in whole blood. However, IUS exposure was signifi-
cantly associated with decreased expression levels in PPEF2 and
XPNPEP1. One reason for the lack of direct correlation between
methylation and expression may be because the methylated loci
for PPEF2 and XPNPEP1 lie within gene bodies, and not the
promoters typically associated with expression levels, [45] and thus
may be only one piece in a complex regulatory network. An
additional reason may be that these genes are functionally relevant
only in utero or shortly after birth, during the time at which
maternal smoking exposure occurred. While the methylation
marks have endured and represent a biomarker of past exposure,
the functionality of the gene may change with developmental time
period and tissue.
Lastly, we acknowledge that the use of the HM27 assay is not an
epigenome-wide interrogation of DNA methylation. Nevertheless,
the HM27 assay served our hypothesis well, since we hypothesized
IUS exposure would be associated with CpG methylation in
promoter regions of genes that regulate expression.
In summary, our results showing an increase in DNA
methylation level at two loci in FRMD4A and Cllorf52 add to
the growing evidence that IUS exposure in humans has epigenetic
consequences for the offspring, some of which may persist
throughout childhood. Though the long term health implications
of these loci are currently unknown and require further
investigation, their implication in nicotine dependence and lung
homeostasis suggests their potential contribution to the develop-
ment of disease in later life.
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